13 May 2019 | News
Board of Directors of the Company recommended a Dividend at the rate of Rs. 105 per equity share for the 12 months period ended March 31, 2019
GlaxoSmithKline Consumer Healthcare Limited declared its financial results for the fourth quarter and full year ended March 31, 2019. The Revenue for the company recorded a growth of 9%. The quarter reported revenue of Rs. 1,286 crores, while the PBT is at Rs. 426 crores, which is an increase of 34% compared to last quarter. The quarter also witnessed a volume growth at 6.5%. For the full year, the revenue is Rs. 4,782 crores which are an increase by 9.3% (Comparable* revenue growth of 12%) and the PBT is at Rs. 1,512 crores, which is an increase by 41% compared to last year.
The Board of Directors of the Company recommended a Dividend at the rate of Rs. 105 per equity share of Rs. 10 each for the year ended March 31, 2019.
Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “I am extremely satisfied with the consistent growth that we witnessed in this financial year, especially on Volume growth in our health drinks portfolio and the share gain achieved by our lead brand Horlicks. In the last quarter, we successfully carried out exciting unique initiatives like the Boost Sports Meet and Horlicks Exam Time. These initiatives, along with our unflinching commitment towards innovation have significantly strengthened our position in the high-science range and will further reinforce our leadership in the HFD category.”
“Another highlight has been our rural coverage, which has increased to 24,000 villages through Rural sub-distributors and Village Level Entrepreneurs (VLE’s) across the 9 States where we operate. As a company, we will continue to drive the nutrition agenda for the country through various initiatives like ‘Horlicks Swasthya Abhiyan’, which are also in line with Government’s National Nutrition Mission,” Mr. Saluja added.
*Comparable: Reflecting the accounting impact of GST (Excise and other tax costs under an earlier regime, now subsumed under GST and netted from Turnover in base)
Update on strategic review: